INTERPACE BIOSCIENCES, INC. (IDXG) Form 8-K — Nov 17, 2026
Interpace Biosciences reported Q3 2026 revenue of $10.4 million, up 18% year-over-year, with thyroid volume up 7% and thyroid revenue up 18%. Gross margin expanded to 69% from 62%, and Adjusted EBITDA rose to $2.1 million (20% margin) from $1.3 million (14%). However, the company swung to a $1.5 million GAAP loss from continuing operations versus $1.0 million income a year ago, driven by approximately $4.1 million of non-recurring stock compensation and legal expenses. The company remains debt-free with $2.9 million in cash.
Key figures
- Revenue
- 10373000
- Total Debt
- 0
- Revenue Yoy
- 18%
- Total Assets
- 37468000
- Cash Position
- 2929000
- Q3 2025 revenue
- 8756000
- Ttm thyroid revenue
- 38000000
- Gross margin q3 2025
- 62%
- Gross margin q3 2026
- 69%
- Operating loss q3 2026
- 2400000
- Adjusted ebitda q3 2025
- 1263000
- Adjusted ebitda q3 2026
- 2072000
- Nine month revenue 2025
- 29504000
- Nine month revenue 2026
- 28537000
- Cash collections q3 2026
- 9100000
- Non recurring charges q3
- 4100000
- Thyroid volume growth yoy
- 7%
- Thyroid revenue growth yoy
- 18%
- Adjusted ebitda margin q3 2025
- 14%
- Adjusted ebitda margin q3 2026
- 20%
- Nine month revenue 2025 pro forma
- 25311000
- Avg thyroid revenue per test growth
- 11%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.